Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fulcrum Therapeutics Inc (FULC)

Fulcrum Therapeutics Inc (FULC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

FULC : 3.44 (-1.15%)
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FULC : 3.44 (-1.15%)
Pacira's Exparel Receives Permanent New Product-Specific J-Code

Pacira BioSciences PCRX announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code (J0666) for its lead pain-management drug, Exparel (bupivacaine...

KRYS : 195.42 (+5.38%)
FULC : 3.44 (-1.15%)
ANIP : 62.01 (+6.22%)
PCRX : 17.63 (-0.40%)
Zevra Stock Surges Close to 70% in 3 Months: Here's Why

Zevra Therapeutics, Inc. ZVRA obtained FDA approval for arimoclomol capsules for the treatment of Niemann-Pick disease type C (NPC) in September. The drug will be marketed under the brand name Miplyffa.The...

ZVRA : 8.82 (+0.11%)
KRYS : 195.42 (+5.38%)
FULC : 3.44 (-1.15%)
ANIP : 62.01 (+6.22%)
RARE's Wilson Disease Candidate Betters Standard Therapy in Study

Ultragenyx Pharmaceutical RARE reported positive updates from the Stage 1 cohorts of its phase I/II/III Cyprus2+ study evaluating UX701, an investigational AAV9 gene therapy, to treat Wilson disease. Stage...

KRYS : 195.42 (+5.38%)
RARE : 50.26 (-0.34%)
FULC : 3.44 (-1.15%)
ANIP : 62.01 (+6.22%)
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag

Ionis Pharmaceuticals, Inc. IONS announced that the FDA has granted a Fast Track designation to its investigational RNA-targeted therapy zilganersen for treating Alexander disease (AxD), an ultra-rare...

KRYS : 195.42 (+5.38%)
FULC : 3.44 (-1.15%)
IONS : 39.07 (+1.59%)
ANIP : 62.01 (+6.22%)
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims

Cassava Sciences SAVA has agreed to pay a $40 million fine to settle charges from the U.S. Securities and Exchange Commission (SEC) over allegedly misleading statements about the results of its 2020 mid-stage...

KRYS : 195.42 (+5.38%)
FULC : 3.44 (-1.15%)
ANIP : 62.01 (+6.22%)
SAVA : 25.51 (+0.67%)
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies

Shares of Biomea Fusion BMEA gained 9.1% on Thursday after the FDA lifted the clinical hold it had earlier placed on the company’s ongoing early to mid-stage studies evaluating its lead candidate, BMF-219,...

KRYS : 195.42 (+5.38%)
FULC : 3.44 (-1.15%)
BMEA : 8.14 (-0.49%)
ANIP : 62.01 (+6.22%)
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study

Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study of its investigational candidate, barzolvolimab, which is being developed for...

CLDX : 26.14 (-1.25%)
KRYS : 195.42 (+5.38%)
FULC : 3.44 (-1.15%)
ANIP : 62.01 (+6.22%)
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals

Roche RHHBY announced positive top-line data from a late-stage study of its marketed drug, Gazyva/Gazyvaro (obinutuzumab), to treat patients with active lupus nephritis (LN). The phase III REGENCY study...

KRYS : 195.42 (+5.38%)
FULC : 3.44 (-1.15%)
ANIP : 62.01 (+6.22%)
RHHBY : 37.5450 (-1.64%)

Barchart Exclusives

1 Stock I Would Never Sell
This 'Magnificent Seven' stock is a clear winner for long-term investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar